In agreement with the literature data, while RET-rearranged advanced NSCLC seems to be responsive to classic platinum-based cytotoxic therapy, it appears to be scarcely sensitive to immunotherapy in the form of immune checkpoint inhibitors (being a “cold” tumor with a low tumor mutational burden). The gene discussed is RET; the disease is neoplasm.